Skip to content
Back to explorer
Printable monograph

RET inhibitor

Selpercatinib

Retevmo · Selp

RET inhibitor · approved 2020 · 11 citations

Up to date· through 2026
Fairly sourced5/9 · 5 signals
  • Met: 11 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 6y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2026
  • Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A selective RET inhibitor whose cardiometabolic signature includes hypertension and creatinine rise.

ModerateRET inhibitor
RET fusion-positive NSCLCRET fusion-positive thyroid cancerRET-mutant medullary thyroid cancer

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
Highly protein-bound RET inhibitor not expected to be appreciably dialyzed; no adjustment for mild-moderate impairment, severe impairment/dialysis not characterized (use with caution), with modifications driven by hypertension/QTc/hepatotoxicity rather than CrCl.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
None on the excerpted label
Label: RETEVMO, Sep 2026. FDA label section.
Pseudo-AKI
Documented to raise creatinine by blocking its tubular secretion — an isolated creatinine rise on this agent may be pseudo-AKI, not true injury. Confirm with a cystatin-C-based or measured GFR before holding therapy.
Pseudo-AKI in the injury atlas.
§01

Signature kidney injury

Signature lesion

Representative grade ≥3 incidence19.7%

Hypertension is among the most common adverse events in LIBRETTO-001 (a frequent grade >=3 event), and a reversible serum-creatinine increase is also recognized. A single-center hereditary-MTC series found hypertension in ~26% on selective RET inhibitors. Reported rate: grade >=3 hypertension in 19.7% — 837 patients with RET-activated advanced/metastatic solid tumors receiving selpercatinib monotherapy (20 mg once daily to 240 mg twice daily in phase I, 160 mg twice daily in phase II), median follow-up 45.4 months (Raez 2024, PMID 39471424).Source: Raez et al., Oncologist 2024

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Hypertension within the first weeks to months; creatinine changes early.

Distilled from: “Hypertension within the first weeks to months; creatinine changes early.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Grade >=3 hypertension in 14% of RET fusion-positive NSCLC patients in LIBRETTO-001, the most common grade >=3 adverse event.

    Not the same figure as §01's 19.7%. §01 is grade ≥3 hypertension across all 837 patients after about 4 years of follow-up; this row is grade ≥3 hypertension in the RET-fusion lung-cancer patients of the first, shorter analysis.

  2. Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence

    Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

  3. Pseudo-AKIRarequalitative — no citable incidence

    The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.

  4. Glomerular Injury / ProteinuriaRarequalitative — no citable incidence

    A single biopsy-worked-up, dose-responsive nephropathy case - distinct from the transporter creatinine artifact.

  5. SIADH / HyponatremiaRarequalitative — no citable incidence

    Two drug-specific reports: SIADH with positive dechallenge, and tubular damage with symptomatic hyponatremia.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

19.7%grade ≥3 incidence

Representative grade ≥3 incidence

SeverityModerate
ReversibilityReversible
Evidence11 citations
Nephron map

Hypertension strikes: Glomerulus, Vasculature / Endothelium.

Glomerulus — struck by HypertensionFiltration barrier (podocytes + endothelium)
Vasculature / Endothelium — struck by HypertensionGlomerular & peritubular capillaries
Proximal Tubule — not involved
Distal Tubule / Collecting Duct — not involved

Hypertension

Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.

§03

Kidney injury

Deep divePseudo-AKI: the creatinine rises and the kidney is fineCreatinine does not only filter — a fifth of it is pushed into the urine by tubular transporters, and a drug that blocks those transporters raises the number without touching the glomerulus, producing a rise that looks like acute kidney injury on every axis except the one that matters.

Mechanism of kidney injury

Hypertension is an on/near-target vascular effect of RET-pathway inhibition (with endothelial/nitric-oxide and vascular-tone contributions shared by many kinase inhibitors). The creatinine rise is thought to reflect, at least in part, inhibition of tubular creatinine secretion (pseudo-AKI) rather than true GFR decline, although hemodynamic (hypertension-mediated) effects may contribute.

Clinical presentation

New or worsened hypertension; mild reversible creatinine elevation without active sediment, with a stable cystatin C-based eGFR in the transporter-mediated cases. QT prolongation and transaminitis are other class effects to monitor.

Management

Standard antihypertensive therapy (and lifestyle measures); dose-interrupt then reduce for medically uncontrolled BP, and hold for severe/refractory hypertension. Isolated creatinine rise usually warrants monitoring and a cystatin C check; evaluate for true AKI if progressive or accompanied by proteinuria/active sediment.Lesion-level management framework

Risk factors

  • Pre-existing hypertension
  • Cardiovascular disease
  • Concurrent nephrotoxins or QT-prolonging drugs

Prevention

  • Optimize antihypertensives before/during therapy
Anticancer mechanism· how it treats cancer

Highly selective RET kinase inhibitor active against RET fusions and activating mutations; approved for RET fusion-positive NSCLC and thyroid cancers and RET-mutant medullary thyroid cancer.

§04

Clinical depth

Renal dose adjustment

Per label, no dosage modification is recommended across mild to severe renal impairment (eGFR 15-89 mL/min/1.73 m2, MDRD); the recommended dosage has not been established in end-stage renal disease, and dialysis is not studied. Weight-based dosing; modifications are driven by hypertension, QTc, hepatotoxicity, and hemorrhage.

Dialyzability & ESKD dosing

Highly protein-bound oral small molecule; not expected to be appreciably dialyzed. No validated ESKD dosing.

Differential diagnosis

Drug-induced hypertension vs essential/secondary causes; transporter-mediated pseudo-AKI (stable cystatin C, bland urine) vs true AKI (prerenal from poorly controlled BP, ATN, or AIN). A flat cystatin C with a creatinine bump indicates the transporter effect.

Monitoring

  • Blood pressure at baseline, after 1 week, at least monthly, and as clinically indicated
  • Serum creatinine periodically; cystatin C-based eGFR if a true GFR change is suspected
  • ECG/QTc and liver enzymes per label

Key trials & series

  • LIBRETTO-001 (RET fusion-positive NSCLC and thyroid; RET-mutant MTC)
  • LIBRETTO-431 (first-line RET fusion-positive NSCLC)
  • Hamidi 2024 hereditary-MTC RET-inhibitor safety series

Clinical pearls

  • Treat the blood pressure and check a cystatin C before assuming the creatinine rise means true GFR loss.
  • Hypertension is the principal renal-relevant signal — manage it to keep patients on effective RET-directed therapy.
  • Co-monitor QTc, since selective RET inhibitors prolong it and several antihypertensive/antiemetic co-medications also do.
  • A biopsy-worked-up, dose-responsive nephropathy with nephrotic features is attributed to selpercatinib — separate from its transporter-mediated creatinine artifact.
  • Two independent reports attribute dysnatremia to selpercatinib: SIADH improving on discontinuation (with successful reduced-dose resumption) and tubular damage with symptomatic hyponatremia and polyuria.
§05

References

8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

8 references · 2020–2025 · 4 since 2023
202020: 1 citation2021: 1 citation2022: 2 citations2024: 2 citations2025: 2 citations20202025

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over timeRaez LE et al. · The Oncologist · 2024 · PMID 39471424Source of the stored incidence: Grade ≥3 treatment-emergent AEs
  2. 2.LandmarkEfficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.Drilon A et al. · N Engl J Med · 2020 · PMID 32846060Pivotal LIBRETTO-001 NSCLC results listing hypertension among the most common adverse events.
  3. 3.Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.Subbiah V et al. · Lancet Oncol · 2022 · PMID 36108661Basket-trial safety data including hypertension across tumor types.
  4. 4.Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma.Hamidi S et al. · Thyroid · 2024 · PMID 39630530Single-center hMTC series quantifying hypertension (~26%) and other AEs with selpercatinib/pralsetinib.
  5. 5.Targeted Cancer Therapies Causing Elevations in Serum Creatinine Through Tubular Secretion Inhibition: A Case Report and Review of the Literature.Mach T et al. · Can J Kidney Health Dis · 2022 · PMID 35756332Supports a transporter-mediated (pseudo-AKI) interpretation of TKI creatinine elevation, confirmable with cystatin C.
  6. 6.Navigating the Complexities of Cancer Treatment-Induced Hypertension.Arriola-Montenegro J et al. · J Cardiovasc Dev Dis · 2025 · PMID 40558670Reviews mechanisms and management of kinase-inhibitor-associated hypertension.
  7. 7.Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.Tonooka A et al. · J Nippon Med Sch · 2021 · PMID 34840210Onconephrology review of TKI-associated renal and vascular complications.
  8. 8.A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene-Positive Non-Small Cell Lung Cancer.Tanaka Y et al. · Respirol Case Rep · 2025 · PMID 41036187SIADH attributed to first-line selpercatinib, improving on discontinuation with successful reduced-dose resumption.
Case reports — ranked by strength· 3
FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

No dosage modification is recommended for patients with mild to severe renal impairment [estimated Glomerular Filtration Rate (eGFR) ≥15 to 89 mL/min, estimated by Modification of Diet in Renal Disease (MDRD) equation]. The recommended dosage has not been established for patients with end-stage renal disease (ESRD) [see Clinical Pharmacology ( 12.3 )] .

Kidney rows of the label's dosage tables

From the RETEVMO label (Sep 2026) · DailyMed

No row of this label's 5 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 1,396 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 6 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Glomerular Injury / Proteinuriacorroborated · ROR 8.56 · 11 of 16 reports look like one case filed repeatedly; without them ROR 2.68 (95% CI 1.11–6.44) — on the terms that name the lesion (ROR 5.49 · IC025 0.13)
  • Hypertensioncorroborated · ROR 4.44 — on the terms that name the lesion (ROR 5.50 · IC025 2.00)
  • SIADH / Hyponatremiacorroborated · ROR 3.37 — on the terms that name the lesion (ROR 9.62 · IC025 1.15)
  • Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
  • Pseudo-AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
Glomerular Injury / Proteinuria
ROR 8.5695% CI 5.23–14.02· 16 reports· IC025 2.00· 11 of 16 reports look like one case filed repeatedly; without them ROR 2.68 (95% CI 1.11–6.44)
Hypertension
ROR 4.4495% CI 3.63–5.44· 101 reports· IC025 1.75
Thrombotic Microangiopathy
ROR 4.0695% CI 1.52–10.82· 4 reports· IC025 −0.14 · IC025 does not clear 0
Hemorrhagic Cystitis
ROR 3.5395% CI 2.13–5.88· 15 reports· IC025 0.88· 11 of 15 reports look like one case filed repeatedly; without them ROR 0.94 (95% CI 0.35–2.52), which does not clear 1
SIADH / Hyponatremia
ROR 3.3795% CI 2.06–5.51· 16 reports· IC025 0.85
Electrolyte Disturbance
ROR 2.8795% CI 2.03–4.05· 33 reports· IC025 0.93
FAERS outcomes & reporting trend· 14.8% of reports w/ death · 31.7% w/ hospitalization
14.8%

Reported with a death outcome

207 of 1,396 reports

31.7%

Reported with hospitalization

443 of 1,396 reports

Reports per year

  • 2015: 0 reports
  • 2016: 0 reports
  • 2017: 0 reports
  • 2018: 0 reports
  • 2019: 0 reports
  • 2020: 82 reports
  • 2021: 166 reports
  • 2022: 214 reports
  • 2023: 216 reports
  • 2024: 302 reports
  • 2025: 206 reports
  • 2026: 210 reports

Reports received per year, 2015–2026 · most recent year is partial.

FAERS adverse-event signal — all organ systems· 11 systems · 1,396 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. Showing the top 10 of 11 classified systems; 1 lower-ranked system is not drawn. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 1.1595% CI 0.69–1.92· 15 AKI reports· IC025 −0.63·no disproportionate AKI reporting signal (CI spans 1).
Renal & urinary
Urinary Tract Infection32Blood Creatinine Increased31
Hepatobiliary
Hepatic Function Abnormal49Alanine Aminotransferase Increased43Aspartate Aminotransferase Increased43Hepatotoxicity36Liver Function Test Increased30
Gastrointestinal
Diarrhoea72Nausea40Dry Mouth39
General / constitutional
Fatigue68Pyrexia50Oedema Peripheral33
Vascular
Hypertension70Blood Pressure Increased27
Immune / infection
Hypersensitivity65
Skin
Rash61
Respiratory
Pleural Effusion28Cough27
Cardiac
Electrocardiogram Qt Prolonged39
Metabolic & electrolyte
Decreased Appetite36
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Selpercatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Pralsetinib

Gavreto · RET inhibitor

Profile

Hypertension; rare AKI.

HTNPREPSEUDO
Mild#1 · 75% phenotype match

Brigatinib

Alunbrig · ALK TKI

Profile

Creatinine elevation; usually benign.

PSEUDOPREHTN
Mild#2 · 64% phenotype match

Lorlatinib

Lorbrena · ALK TKI

Profile

Edema and metabolic effects.

PSEUDOPREGLOM
Mild#3 · 64% phenotype match

Momelotinib

Ojjaara · JAK/ACVR1 inhibitor

Profile

2023 myelofibrosis JAK inhibitor.

PSEUDOPRE
Mild#4 · 63% phenotype match

Vimseltinib

Romvimza · CSF1R tyrosine kinase inhibitor

Profile

A clean-kidney targeted TKI — watch the CPK, not the nephron.

PSEUDOPRE
Mild#5 · 62% phenotype match

Adagrasib

Krazati · KRAS G12C inhibitor

Profile

Creatinine rise; emerging data.

PREGLOMPSEUDO
Mild#6 · 57% phenotype match
Compare Selpercatinib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Other kinase inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1PexidartinibMild
  2. 1RipretinibMild
  3. 3AvapritinibMild
  4. 3FedratinibMild
  5. 3MidostaurinMild
  6. 3MomelotinibMild
  7. 3QuizartinibMild
  8. 3VimseltinibMild
  9. 9PralsetinibMild
  10. 9RuxolitinibMild
  11. 11PacritinibModerate
  12. 12Selpercatinib· this agentModerate
  13. 13GilteritinibFAERS AKIModerate

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.